Aligos Therapeutics Statistics
Aligos Therapeutics (5WK0) Stock Statistics & Valuation Metrics
Total Valuation
Aligos Therapeutics has a market cap or net worth of EUR 10.64M. The enterprise value is EUR 39.06M.
- Market Cap
- EUR 10.64M
- Enterprise Value
- EUR 39.06M
Share Statistics
Aligos Therapeutics has 6,248,478 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 6,248,478
- Owned by Insiders
- 46.67%
- Owned by Institutions
- 38.75%
Financial Efficiency
Aligos Therapeutics’s return on equity (ROE) is -0.45 and return on invested capital (ROIC) is -123.88%.
- Return on Equity (ROE)
- -0.45
- Return on Assets (ROA)
- -0.27
- Return on Invested Capital (ROIC)
- -123.88%
- Return on Capital Employed (ROCE)
- -1.31
- Revenue Per Employee
- 26.66K
- Profits Per Employee
- -295.04K
- Employee Count
- 82
- Asset Turnover
- 0.02
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Aligos Therapeutics is -0.26. Aligos Therapeutics’s PEG ratio is 0.00.
- PE Ratio
- -0.26
- PS Ratio
- 0.31
- PB Ratio
- 1.54
- Price to FCF
- -0.15
- Price to Operating Cash Flow
- -0.25
- PEG Ratio
- 0.00
Income Statement
In the last 12 months, Aligos Therapeutics had revenue of 2.19M and earned -24.19M in profits. Earnings per share was -2.45.
- Revenue
- 2.19M
- Gross Profit
- 1.26M
- Operating Income
- -87.98M
- Pretax Income
- -23.88M
- Net Income
- -24.19M
- EBITDA
- -22.95M
- Earnings Per Share (EPS)
- -2.45
Cash Flow
In the last 12 months, operating cash flow was -68.37M and capital expenditures -289,000, giving a free cash flow of -68.66M billion.
- Operating Cash Flow
- -68.37M
- Free Cash Flow
- -68.66M
- Free Cash Flow per Share
- -6.56
Dividends & Yields
Aligos Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -654.07%
- Earnings Yield
- -377.13%
Stock Price Statistics
- Beta
- 1.13
- 52-Week Price Change
- -63.61%
- 50-Day Moving Average
- 4.41
- 200-Day Moving Average
- 5.11
- Relative Strength Index (RSI)
- 16.83
- Average Volume (3m)
- 83
Important Dates
Aligos Therapeutics upcoming earnings date is Mar 11, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 06, 2026
- Next Earnings Date
- Mar 11, 2027
- Ex-Dividend Date
- ―
Financial Position
Aligos Therapeutics as a current ratio of 3.90, with Debt / Equity ratio of 9.80%
- Current Ratio
- 3.90
- Quick Ratio
- 3.90
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 0.57
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, Aligos Therapeutics has paid 314.00K in taxes.
- Income Tax
- 314.00K
- Effective Tax Rate
- -0.01
Enterprise Valuation
Aligos Therapeutics EV to EBITDA ratio is 0.14, with an EV/FCF ratio of 0.13.
- EV to Sales
- -0.26
- EV to EBITDA
- 0.14
- EV to Free Cash Flow
- 0.13
- EV to Operating Cash Flow
- 0.13
Balance Sheet
Aligos Therapeutics has EUR 31.09M in cash and marketable securities with EUR 11.90M in debt, giving a net cash position of EUR 19.19M billion.
- Cash & Marketable Securities
- EUR 31.09M
- Total Debt
- EUR 11.90M
- Net Cash
- EUR 19.19M
- Net Cash Per Share
- EUR 3.07
- Tangible Book Value Per Share
- EUR 1.08
Margins
Gross margin is 99.24%, with operating margin of -215.55%, and net profit margin of -197.01%.
- Gross Margin
- 99.24%
- Operating Margin
- -215.55%
- Pretax Margin
- -186.65%
- Net Profit Margin
- -197.01%
- EBITDA Margin
- -182.64%
- EBIT Margin
- -186.65%
Analyst Forecast
The average price target for Aligos Therapeutics is EUR 45.49, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
- Price Target
- EUR 45.49
- Price Target Upside
- 2350.81% Upside
- Analyst Consensus
- Moderate Buy
- Analyst Count
- 1
- Revenue Growth Forecast
- 1121.13%
- EPS Growth Forecast
- 51.71%

